Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
January 23 2023 - 7:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of January 2023 (Report No. 3)
Commission file number: 001-39957
NLS PHARMACEUTICS LTD.
(Translation of registrant’s name into English)
The Circle 6
8058 Zurich, Switzerland
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
CONTENTS
On
January 23, 2023, NLS Pharmaceutics Ltd., or the Registrant, issued a press release titled: “NLS Pharmaceutics announces new in-vitro
data highlighting Quilience® (mazindol ER) unique dual mechanism of action involving significant Orexin-2 receptor activity.”
A copy of this press release is furnished herewith as Exhibit 99.1.
This
report is incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-262489, and 333-268690
and 333-269220), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is
submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
NLS Pharmaceutics Ltd. |
|
|
|
Date: January 23, 2023 |
By: |
/s/ Alexander Zwyer |
|
|
Name: |
Alexander Zwyer |
|
|
Title: |
Chief Executive Officer |
2
NLS Pharmaceutics (NASDAQ:NLSP)
Historical Stock Chart
From May 2024 to Jun 2024
NLS Pharmaceutics (NASDAQ:NLSP)
Historical Stock Chart
From Jun 2023 to Jun 2024